Alpine Immune Sciences (ALPN) Reports Q2 Loss of $0.53/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alpine Immune Sciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 11, 2020 4:05 PM EDT- Signed option to license worldwide rights to ALPN-101 with AbbVie -
- Received $60 million upfront cash payment from AbbVie; eligible to receive up to $805 million for exercise of the option and success-based development, regulatory and commercial milestones -
- Dosed first patient in NEON-1 Phase 1 trial of ALPN-202 in patients with advanced malignancies -
- Raised $60 million in July private placement led by Omega Funds -
- Conference call and webcast today at 4:30 p.m. ET -
... More
